Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
Open Access
- 1 September 2021
- journal article
- research article
- Published by Elsevier in The Lancet Global Health
- Vol. 9 (9) , e1305-e1313
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (D43TW009340)
- National Institutes of Health (U54CA190152)
- National Institutes of Health (T32CA11633911)
- National Institutes of Health (K01TW011470)
- National Institutes of Health (UM1CA121947)
- National Institutes of Health (R25CA057711)
- National Institutes of Health (P30CA233709)
- National Institutes of Health (K01TW009488)
- Pfizer Foundation
- Government of South Australia
- U.S. Department of Health and Human Services
This publication has 26 references indexed in Scilit:
- Disability weights for the Global Burden of Disease 2013 studyThe Lancet Global Health, 2015
- Treatment Outcomes in AIDS-Related Diffuse Large B-cell Lymphoma in the Setting Roll Out of Combination Antiretroviral Therapy in South AfricaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2013
- Early Experience after Developing a Pathology Laboratory in Malawi, with Emphasis on Cancer DiagnosesPLOS ONE, 2013
- Cost effectiveness of strategies to combat breast, cervical, and colorectal cancer in sub-Saharan Africa and South East Asia: mathematical modelling studyBMJ, 2012
- GEMOX‐R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large‐cell lymphoma: a phase II studyEuropean Journal of Haematology, 2007
- Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2006
- Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010Blood, 2005
- Introduction of Combined CHOP Plus Rituximab Therapy Dramatically Improved Outcome of Diffuse Large B-Cell Lymphoma in British ColumbiaJournal of Clinical Oncology, 2005
- Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphomaCancer, 2005
- Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP ChemotherapyLeukemia & Lymphoma, 2003